GoodRx Holdings, Inc.
GoodRx Holdings, Inc. operates a consumer healthcare platform that helps Americans compare prescription prices, access discount pricing, and manage medication affordability. The company monetizes traffic through prescription transaction fees, subscription offerings, and pharma manufacturer solutions, while also expanding into telehealth and other healthcare services.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaConsumer prescription pricing, discount codes, and transaction-based savings at pharmacies.
Paid consumer plans such as GoodRx Gold that provide enhanced medication savings.
Commercial services for drug makers, including patient access and affordability programs.
Tuotteet
Raportoitu · osuus liikevaihdosta- Prescription Transactions Revenue68,3 %
- Pharma Direct Revenue19,0 %
- Subscription Revenue10,5 %
- Other Revenue2,2 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
GoodRx sells to consumers seeking lower out-of-pocket prescription costs, but its commercial relationships also span pharmacies, PBMs, and pharmaceutical manufacturers. Consumers use the platform for price transparency and savings, while partners use it to drive volume, improve adherence, and reach patients more efficiently.
Individuals using GoodRx to compare prices, access discount codes, and save on prescriptions.
PBMs provide cash-network pricing and discounts that GoodRx routes to consumers to generate transactions.
Pharmacies partner with GoodRx to reduce walk-away patients and increase prescription volume.
Drug makers buy access and affordability solutions to support patient uptake and adherence.
Providers and patients use adjacent digital tools and telehealth offerings tied to the platform.
Strategia
GoodRx is focused on expanding from prescription savings into a broader consumer healthcare platform while increasing monetization from its existing user base. Management is also emphasizing strategic partnerships, deeper pharmacy relationships, and selective acquisitions to strengthen distribution and improve unit economics.
Using more offerings per consumer raises lifetime value without proportionate acquisition cost.
PBMs, pharmacies, and manufacturers are core to pricing, traffic, and monetization.
This segment is growing faster and can diversify revenue away from consumer transaction dependence.
Awareness is a key barrier to adoption in a consumer healthcare market with many alternatives.
Maantiede
GoodRx generates all of its revenue in the United States, and its platform is built around U.S. prescription pricing, pharmacy networks, and healthcare rules. This makes the business highly exposed to U.S. retail pharmacy dynamics, PBM contracting, and federal and state healthcare policy changes.
Riskit
GoodRx depends on a limited set of PBMs, pharmacies, and transaction-processing vendors, so partner concentration and contract changes can quickly affect pricing and revenue. The company is also exposed to U.S. healthcare regulation, retail pharmacy disruption, and competition for consumer attention, all of which can reduce transaction volume or weaken its value proposition.
- Retail pharmacy disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Store closures and volume declines reduce prescription transactions processed through the platform.
Kohdistuu: Broader retail pharmacy landscape changes
- PBM and partner concentrationVaikutus: KorkeaTodennäköisyys: Matala
A limited number of PBMs generate a significant portion of discounted prices and revenue.
Kohdistuu: Three largest PBM customers accounted for 22% of revenue in 2025
- U.S. healthcare regulationVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Federal and state changes to healthcare spending and medication pricing can alter the economics of the platform.
Kohdistuu: Prescription affordability and pricing transparency business model
- Competition and consumer awarenessVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company says awareness is a primary barrier to adoption, so rivals can limit growth.
Kohdistuu: Consumer internet and healthcare savings tools
- Platform and cybersecurity riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The business relies on apps, websites, pricing data, and transaction processing infrastructure.
Kohdistuu: Digital healthcare platform operations
Kirjanpito
Harkinnanvaraiset erätDifferent revenue lines have different timing and drivers, so mix changes affect comparability.
Vaikutus: Prescription transactions, subscriptions, and pharma manufacturer solutions
Changes in subscription plan counts directly affect recurring revenue and growth rates.
Vaikutus: GoodRx Gold and other subscription offerings
Acquisitions can add intangible assets, goodwill, and integration-related costs.
Vaikutus: VCRx acquisition and future strategic acquisitions
Platform investment affects operating expense timing and asset balances.
Vaikutus: Product development and technology spending
Holding company status and debt covenants limit upstream distributions and dividend capacity.
Vaikutus: Parent company liquidity and capital allocation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
OptimizeRx Corp
OPRX · Services-Business Services, NEC
OptimizeRx Corp is a U.S.-based digital healthcare technology company that connects life sciences brands with healthcare professionals and patients through…
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Pfizer, Inc
PFE · Pharmaceutical Preparations
111, Inc.
YI · Retail-Drug Stores and Proprietary Stores
Viatris Inc
VTRS · Pharmaceutical Preparations
Prestige Consumer Healthcare Inc.
PBH · Pharmaceutical Preparations
Päivitetty: 24.9.2026